在心力衰竭的临床前模型中,ANTXR1阻塞增强了心脏功能
Nicola Boccella1, GuoJun Yu2, Steven Seaman2
1Neural Development Section, Mouse Cancer Genetics Program (MCGP), National Cancer Institute (NCI), NIH, Frederick, MD, USA.
Nature cardiovascular research
|October 2, 2025
概括
缺乏治疗心脏病的方法. 阻断ANTXR1 (一种参与原去除的蛋白质) 在心力衰竭模型中改善了心脏功能和运动耐受性,提供了一个新的治疗点.
科学领域:
- 心血管研究研究心血管研究
- 分子生物学分子生物学
- 病理学 病理学 病理学
背景情况:
- 心脏病是全球主要的死亡原因,其特点是纤维化 (过度的原体沉积).
- 目前的治疗方法不能有效地针对心脏病中的纤维化通路.
- ANTXR1/TEM8是一种跨膜蛋白,在原去除和伤害反应中起作用.
研究的目的:
- 为了研究ANTXR1在心力衰竭病原发生中的作用.
- 评估ANTXR1作为潜在的心脏病治疗点.
主要方法:
- 在心力衰竭的小鼠模型中,Antxr1的遗传破坏.
- 用人类中和抗体对抗ANTXR1.1.进行治疗.
- 药理上阻断ANTXR1.1. 的作用.
- 在各种心力衰竭模型 (心肌梗塞,压力过载,肥胖引起的) 中评估心脏功能,纤维化和运动耐受性.
- 关于痕形成和TGFβ介导的重塑的机制研究.
主要成果:
- 对Antxr1和ANTXR1抗体的基因删除治疗预防了肌心梗塞后的心脏恶化.
- 在压力过载和肥胖模型中,ANTXR1阻塞改善了心脏功能和喷射率.
- 改善心脏功能与增强的运动耐受性相关.
- 阻断ANTXR1导致了更好的痕形成,并减少了慢性TGFβ介导的重塑.
结论:
- 在心力衰竭中,ANTXR1介导的原循环是有害的.
- ANTXR1代表了治疗心脏病的可用药物标.
- 针对ANTXR1的治疗策略有望改善心脏病的结果.
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
936
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
936
01:22Heart Failure Drugs: β-Blockers
771
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
771
01:30Heart Failure V: Medical Management
223
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
223
01:22Heart Failure Drugs: Diuretics
807
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
807
01:29Heart Failure II: Pathophysiology
730
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
730